We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

1 hedge funds and large institutions have $10.2K invested in Apellis Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 279 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 323 → 1 (-322)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital invested

Capital invested by funds: $5.56B → $10.2K (-$5.56B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 279

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

109.78% less ownership

Funds ownership: 109.78% → 0% (-110%)

Holders
1
Holders Change
-322
Holders Change %
-99.69%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
279
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$545M
2
ACA
Avoro Capital Advisors
New York
-$492M
3
Morgan Stanley
Morgan Stanley
New York
-$404M
4
State Street
State Street
Massachusetts
-$275M
5
UBS Group
UBS Group
Switzerland
-$250M
Name Holding Trade Value Shares
Change 		Change in
Stake
CL
126
CSS LLC
Illinois
– -$1.72M -42,818 Closed
XT
127
XTX Topco
Cayman Islands
– -$1.67M -41,627 Closed
Vanguard Global Advisers
128
Vanguard Global Advisers
Pennsylvania
– -$1.64M -40,745 Closed
State of Tennessee, Department of Treasury
129
State of Tennessee, Department of Treasury
Tennessee
– -$1.62M -40,180 Closed
Citadel Advisors
130
Citadel Advisors
Florida
– -$1.56M -38,887 Closed
Handelsbanken Fonder
131
Handelsbanken Fonder
Sweden
– -$1.42M -35,400 Closed
CG
132
Carmignac Gestion
France
– -$1.41M -35,127 Closed
BA
133
Bridgewater Associates
Connecticut
– -$1.4M -34,913 Closed
AB
134
Amalgamated Bank
New York
– -$1.4M -34,726 Closed
DS
135
DRW Securities
Illinois
– -$1.35M -33,573 Closed
VIA
136
Virtus Investment Advisers
Connecticut
– -$1.35M -33,462 Closed
OL
137
Odyssean LLC
Connecticut
– -$1.25M -31,032 Closed
Amundi
138
Amundi
France
– -$1.24M -30,721 Closed
CC
139
Carlson Capital
Texas
– -$1.21M -30,000 Closed
SG Americas Securities
140
SG Americas Securities
New York
– -$1.19M -29,601 Closed
Stifel Financial
141
Stifel Financial
Missouri
– -$1.14M -28,220 Closed
YCM
142
Yousif Capital Management
Michigan
– -$1.13M -27,997 Closed
Zurich Cantonal Bank
143
Zurich Cantonal Bank
Switzerland
– -$1.12M -27,921 Closed
JG
144
Jain Global
New York
– -$1.12M -27,793 Closed
State of New Jersey Common Pension Fund D
145
State of New Jersey Common Pension Fund D
New Jersey
– -$1.04M -25,896 Closed
COPPSERS
146
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
– -$1.02M -25,344 Closed
EAM
147
Erste Asset Management
Austria
– -$432K -25,300 Closed
TRSOTSOK
148
Teachers Retirement System of the State of Kentucky
Kentucky
– -$1.01M -25,000 Closed
Manulife (Manufacturers Life Insurance)
149
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$996K -24,765 Closed
TSS
150
Two Sigma Securities
New York
– -$957K -23,779 Closed
4 5
6
7 8

APLS Hedge Fund Activity: Q2 2026 in Review

1 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2026, worth a combined $10.2K — down 100% from $5.56B a quarter earlier.

Sellers outnumbered buyers: 279 funds closed out of APLS and 0 opened new positions — a net loss of 279 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $545M sold.

  • 1 institutional investor held Apellis Pharmaceuticals (APLS) as of Q2 2026, down from 323 in Q1 2026.
  • Funds reported $10.2K of Apellis Pharmaceuticals stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Apellis Pharmaceuticals positions in Q2 2026 and 279 closed out, a net change of -279 holders.
  • The largest Apellis Pharmaceuticals seller in Q2 2026 was BlackRock, an estimated $545M sold.

Based on aggregated 13F filings for Q2 2026.